title: Anabolic effects of PTH and the 'anabolic window'.
abstract: Maximization of the anabolic effects of intermittent administration of parathyroid hormone (PTH) has recently been at the forefront of clinical research in the area of osteoporosis, with the 'anabolic window' concept as its main driving force. The outcome of these attempts, however, has not been encouraging. This article examines whether the concept itself is based on sound evidence, related pathophysiological aspects, and whether the new anti-sclerostin antibodies could have extended anabolic action.
authors: Institute of Musculoskeletal Sciences, Oxford University, Oxford OX3 7LD, UK. Electronic address: Michael.Pazianas@ndorms.ox.ac.uk.
authors: Michael
authors: M
authors: Pazianas
mesh_terms: D045930:Anabolic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D015519:Bone Density / Q000187:drug effects*; D001842:Bone and Bones / Q000187:drug effects*; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy*; D010281:Parathyroid Hormone / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D045930:Anabolic Agents; D010281:Parathyroid Hormone
keywords: PTH; anabolic window; bisphosphonates; bone remodeling; denosumab; sclerostin